Ireland
--:--IST
Starting soon Observational

Correcting Hypocapnia in Aneurysmal Subarachnoid Hemorrhage.

NCT07343232 · tracked via the Priya Life Science China tracker
Sponsor
The Chinese University of Hong Kong, Shenzhen
Phase
Observational
Started
2026-01-01
Last updated
2026-01-15

Condition(s) studied

Aneurysmal Subarachnoid Hemorrhage (aSAH)

Investigational drug(s) / intervention(s)

Normobaric Facemask Oxygencontrol group

Normobaric Facemask Oxygen: Oxygen is to be delivered via a rebreathing facemask (ensuring no one-way valve is present), with a fractional inspired oxygen (FiO2) of 25-41% and an oxygen flow rate of ≤ 5 L/min. The goals are to maintain patient SpO2 \> 95%, PaCO2 between 35-42 mmHg, and, where feasible (particularly in centers with the capability for monitoring), an intracranial pressure (ICP) of \< 15 mmHg.

control group: Using nasal cannula for oxygen inhalation or not using oxygen inhalation at all. Monitor and record the patient's SpO2, systolic blood pressure, diastolic blood pressure, PaCO2, and also monitor the intracranial pressure (ICP) at a center with monitoring capabilities.

Study summary

Based on the clinical observation that over half of the patients in the management of aneurysmal subarachnoid hemorrhage(aSAH) present with spontaneous hyperventilation, which is significantly associated with delayed cerebral ischemia and poor neurological outcomes, this prospective pilot study is designed to investigate the safety and efficacy of normobaric facemask oxygen for hypocapnia in aSAH.

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: 1. Age \> 18 years. 2. Confirmed diagnosis of aneurysmal subarachnoid hemorrhage (aSAH), with the presence of an aneurysm verified by computed tomography (CT), CT angiography (CTA), or digital subtraction angiography (DSA). 3. Hunt-Hess grade II-IV. 4. Presence of hypocapnia on arterial blood gas analysis, defined as PaCO2 \< 35 mmH; 5. PaO2 \> 90 mmHg. Exclusion Criteria: 1. Presence of brain herniation or refractory intracranial hypertension, defined as a baseline intracranial pressure (ICP) \> 25 mmHg that responds poorly to conventional ICP-lowering therapy; 2. Primary respiratory diseases (e.g., chronic obstructive pulmonary disease, severe asthma) known to cause chronically elevated baseline PaCO2; 3. Severe acid-base disturbances other than respiratory alkalosis. 4. Severe cardiac insufficiency, severe hepatic or renal dysfunction, malignant tumors, or other severe comorbidities that significantly impact prognosis; 5. Before the onset of the disease, the mRS score was greater than 2, and there were other factors causing disability. 6. Life expectancy \< 3 months; 7. Any other condition deemed by the investigator to pose a high risk warranting exclusion.

Primary outcome measure(s)

  • modified Rankin Scale (mRS) >3 — 90-day follow-up visit
    The poor neurological outcome was considered to be mRs \>3, indicating severe disability or death. The modified Rankin Scale (mRS) is a commonly used scale for measuring the degree of disability or dependence in the daily activities of people who have suffered a stroke or other causes of neurological disability. (Score Description: 0---No symptoms at all. 1---No significant disability despite symptoms; able to carry out all usual duties and activities. 2---Slight disability; unable to carry out all previous activities, but able to look after own affairs without assistance. 3---Moderate disability; requiring some help, but able to walk without assistance. 4--- Moderately severe disability; unable to walk without assistance and unable to attend to own bodily needs without assistance. 5---Severe disability; bedridden, incontinent and requiring constant nursing care and attention. 6---Dead.
  • Incidence of delayed cerebral injury (DCI) — 30 days after onset
    The presence of new focal neurological signs or a documented decrease in the level of consciousness persisting for at least 1 hour (or a drop of at least 1 point in the total Glasgow Coma Scale score), deemed to be of ischemic origin, after ruling out other causes (such as hydrocephalus, toxic-metabolic disturbances, or seizures); or identification of a new cerebral infarction on CT or MRI imaging.

Trial sites (1)

FacilityCityRegionStatus
School of Medicine Chinese University of Hong Kong-SHENZHEN Shenzhen Guangdong

More The Chinese University of Hong Kong, Shenzhen trials in China

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07343232 on ClinicalTrials.gov ↗ ← All trials in China